Brookline Capital Initiates Coverage On Revolution Medicines with Buy Rating, Announces Price Target of $318

Brookline Capital analyst Leah Rush has initiated coverage on Revolution Medicines (NASDAQ: RVMD) with a Buy rating. The firm has set a price target of $318 for the stock.